ICER panel: hATTR treatments have low value
The Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council (CEPAC) voted unanimously in separate tallies that the long-term value for money was low for hATTR treatments from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Akcea Therapeutics Inc. (NASDAQ:AKCA).
The panel reviewed ICER's evidence reports for Alnylam's Onpattro patisiran and Akcea's Tegsedi inotersen, in which the group found that the treatments, at an annual price of $345,000, were not cost effective at the $150,000 per quality-adjusted life year (QALY) threshold. Alnylam launched Onpattro last month at a net price of $345,000. The biotech said it had agreements in principal with some insurers on a pay-for-performance arrangement for the RNAi therapeutic (see "Agreement to Differ")...